MGC Pharmaceuticals’ golden blanket approach combines multiple elements for better patient efficacy
Stock Insiders: MGC Pharmaceuticals’ ‘golden blanket’ combines multiple elements for better patient efficacy
Health & Biotech
share
Stock Insiders is a new podcast series focussed on investing hosted by renowned business journalist Oriel Morrison.
In this episode Oriel chats to Roby Zomer, founder and managing director of MGC Pharmaceuticals (ASX:MXC)
MGC Pharmaceuticals is a global biopharma company focused on developing and supplying high-quality phytotherapeutics and phytomedicines to patients in Europe, Australasia and North America. The company’s current phytomedicine range includes CannEpil, an orally-administered medical cannabis treatment for drug-resistant (or refractory) epilepsy, and CogniCann, a treatment to improve quality of life in dementia patients.
The company made headlines taking a 40pc stake in ZAM, an AI healthcare platform that’s ‘ahead of market peers’.
To hear more about Roby’s background, company structure, current research and development, global expansion and more.
Click below
